NHS access to Mounjaro (tirzepatide) for weight management is real but tightly rationed and rolling out in phases — and crucially, you cannot apply for it. Eligible patients are identified through GP records and contacted; the NHS has specifically asked people not to approach their GP to request it. Here's who currently qualifies, what changed in 2026, and what your options are if you fall outside the criteria.
What changed in 2026
NHS England initially funded local pilot services (from mid-2025) to prescribe tirzepatide for the highest-need patients. From 1 April 2026, that approach changed: prescribing moved into the GP contract, meaning GP practices can prescribe tirzepatide for obesity for specific patient groups — but participation is optional for practices, so availability genuinely varies by area and even by surgery. Some regions experienced pauses during the handover. A wider eligibility phase ("Cohort 2", with somewhat lower thresholds) has been expected to begin opening from around mid-2026, subject to local rollout.
Who currently qualifies (first phase)
The initial NHS cohort targets the highest clinical need — criteria are substantially stricter than private licensing:
- Age 18 or over
- BMI of 40 or above — adjusted to 37.5+ for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background
- Plus at least four of five qualifying weight-related conditions: type 2 diabetes, high blood pressure, dyslipidaemia (abnormal cholesterol), cardiovascular disease, obstructive sleep apnoea
NHS prescribing also comes wrapped in structured lifestyle support ("wrap-around" services), because the medicine is licensed for use alongside diet and activity change, not instead of it.
Why you can't just ask your GP
Demand vastly exceeds NHS capacity, so the system works by identification rather than application: practices and local prescribing hubs review records, contact eligible patients, and manage numbers. Asking your GP won't accelerate anything — and meeting the criteria on paper still doesn't guarantee access, because it depends on whether your practice has opted in and local service capacity exists. Frustrating, but that's the honest picture.
What if you don't qualify — or can't wait?
Most people interested in weight-loss medication don't meet the current NHS thresholds — they're designed for the most severe cases first. Two things are true at once:
- NHS criteria will widen over time as cohorts open — if you're near the thresholds, staying registered with an engaged GP practice and keeping your records current (weight, conditions) matters
- Private treatment uses the licensed criteria — generally BMI 30+, or 27+ with a weight-related condition — which is where regulated online pharmacies fit. Our guide to qualifying for weight-loss treatment in the UK covers the assessment in detail
Wegovy (semaglutide) follows its own NHS pathway, largely through specialist weight-management services — a separate route worth knowing about if you've been referred.
NHS vs private at a glance
| NHS route | Private route | |
|---|---|---|
| Who qualifies | BMI 40+ (37.5+ some ethnicities) with 4+ qualifying conditions (first phase) | Generally BMI 30+, or 27+ with one weight-related condition |
| How you access it | Identified and contacted — no self-referral | Apply directly; clinical assessment decides |
| Cost | Standard NHS prescription arrangements | Self-funded, price varies by dose |
| Availability | Varies by area and practice opt-in | Subject to clinical suitability and stock |
| Support | Wrap-around lifestyle services | Provider-dependent — check what's included |
Frequently asked questions
Can I get Mounjaro free on the NHS?
Only if you meet the current strict criteria (first phase: BMI 40+, or 37.5+ for some ethnic backgrounds, plus four of five qualifying conditions) and your area/practice is actively prescribing. Eligible patients are contacted — you can't apply.
Should I ask my GP for Mounjaro?
The NHS has asked patients not to — eligibility is identified from records and managed by local prescribing arrangements. Do keep your records accurate and attend reviews for your existing conditions.
When will NHS eligibility widen?
Further cohorts with lower thresholds are planned as the rollout expands — timing varies by area. Check your local ICB's website for its current position.
Is private Mounjaro the same medicine as NHS Mounjaro?
Yes — same manufacturer, same product. The difference is the access route, criteria and funding, not the medicine.
References
- NHS England. Interim commissioning guidance: tirzepatide for the management of obesity.
- NICE. Tirzepatide for managing overweight and obesity (technology appraisal guidance).
- NHS England. GP contract 2026/27 arrangements incorporating tirzepatide prescribing for obesity.
- Example ICB guidance: NHS Cheshire and Merseyside — Tirzepatide (Mounjaro) prescribing statement, 2026.
- GOV.UK. GLP-1 medicines for weight loss and diabetes: what you need to know.